The Prostate Cancer Program (Program) of the UCSF Helen Diller Family Comprehensive Cancer (Center) is a multidisciplinary group of investigators focused on understanding the core biology that drives the clinical behavior of prostate cancer across the full spectrum of the disease. The Prostate Cancer Program comprises 25 basic and clinical scientists from nine departments working together to translate research into advances in the epidemiology, prevention, staging, and treatment of prostate cancer. Program faculty represent membership in five graduate programs: Program in Biological Sciences (PIBS);Biomedical Sciences (BMS);Bioengineering, Pharmaceutical Sciences and Pharmacogenomics (PSPG);and Chemical Biology. The goals of the Program are to promote interdisciplinary research that will allow a better understanding ofthe biology of prostate cancer from the biologic and environmental factors associated with carcinogenesis, through the early detection and disease progression to prognostication, and the biologic basis of disease progression. The ultimate goal is the development of novel intervention strategies that will improve the lives of men who carry a diagnosis of prostate cancer or who are at risk of developing prostate cancer. The Prostate Cancer Program pursues these goals through ongoing work in four major thematic areas: (1) Risk and Oncogenesis;(2) Prognosis and Progression;(3) Biology and Therapeutic Targets;and (4) Disparities, Health Related Quality of Life (HRQOL), and Outcomes. The Program has $9,667,568 in total peer reviewed support for the last grant year. The Program has 16% intra-programmatic and 13% inter-programmatic publications.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Chen, Justin; Weiss, William A (2014) When deletions gain functions: commandeering epigenetic mechanisms. Cancer Cell 26:160-1
Johnson, Brett E; Mazor, Tali; Hong, Chibo et al. (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189-93
Witte, John S; Visscher, Peter M; Wray, Naomi R (2014) The contribution of genetic variants to disease depends on the ruler. Nat Rev Genet 15:765-76
Sufiawati, Irna; Tugizov, Sharof M (2014) HIV-associated disruption of tight and adherens junctions of oral epithelial cells facilitates HSV-1 infection and spread. PLoS One 9:e88803
Sharma, Vineeta; Witkowski, Andrzej; Witkowska, H Ewa et al. (2014) Aberrant hetero-disulfide bond formation by the hypertriglyceridemia-associated p.Gly185Cys APOA5 variant (rs2075291). Arterioscler Thromb Vasc Biol 34:2254-60
Gustafson, William Clay; Meyerowitz, Justin Gabriel; Nekritz, Erin A et al. (2014) Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell 26:414-27
Gable, Jonathan E; Lee, Gregory M; Jaishankar, Priyadarshini et al. (2014) Broad-spectrum allosteric inhibition of herpesvirus proteases. Biochemistry 53:4648-60
Cope, Leslie M; Fackler, Mary Jo; Lopez-Bujanda, Zoila et al. (2014) Do breast cancer cell lines provide a relevant model of the patient tumor methylome? PLoS One 9:e105545
Bankoti, Jaishree; Apeltsin, Leonard; Hauser, Stephen L et al. (2014) In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol 75:266-76
Ilkanizadeh, Shirin; Lau, Jasmine; Huang, Miller et al. (2014) Glial progenitors as targets for transformation in glioma. Adv Cancer Res 121:1-65

Showing the most recent 10 out of 71 publications